Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

Table 4

Multiple regression analysis of preoperative variables with the changes in BCVA between the baseline and 3 months after the initial IVR.

Variable	𝑟	𝑃 value
Gender	−0.19	.15
(female = 0, male = 1)
Smoking	−0.14	.30
(nonsmoker = 0, present and ever smokers = 1)
Hypertension	0.11	.41
(no history = 0, present = 1)
Diabetes Mellitus	0.041	.76
(no history = 0, present = 1)
Phenotype	−0.38	.013
(PCV = 0, tAMD = 1)
Baseline BCVA (LogMAR)	−0.36	.026
Baseline CRT (μm)	0.11	.40
Subretinal hemorrhage (≦1 DA = 0, >1 DA = 1)	0.21	.11
Greatest linear dimension (μm)	0.15	.27

BCVA: best-corrected visual acuity, IVR: intravitreous ranibizumab, CRT: central retinal thickness, and DA: disc area. r: partial correlation coefficient.